50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How to profit from the coming boom in gold (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How to profit from the coming boom in gold (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How to profit from the coming boom in gold (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How to profit from the coming boom in gold (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How to profit from the coming boom in gold (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How to profit from the coming boom in gold (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The 3-Stock Retirement Blueprint (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
How to profit from the coming boom in gold (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
How to profit from the coming boom in gold (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
NASDAQ:NVUS

Novus Therapeutics - NVUS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$2.70
$2.95
50-Day Range
$9.85
$16.50
52-Week Range
$4.50
$27.32
Volume
11,426 shs
Average Volume
78,851 shs
Market Capitalization
$3.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NVUS stock logo

About Novus Therapeutics (NASDAQ:NVUS) Stock

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Receive NVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVUS Stock News Headlines

Is Novus Therapeutics (NVUS) A Good Stock To Buy Now?
Novus Therapeutics EPS misses by $3.76
Why Novus Therapeutics Is Trading Higher Today
Novus Therapeutics rallies on Anelixis Therapeutics buy
Novus Therapeutics Inc Registered Shs - Profile
Why Novus Therapeutics Is Trading Lower Today
Novus Therapeutics EPS misses by $0.31
Novus Therapeutics Inc.
See More Headlines

Receive NVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVUS Company Calendar

Last Earnings
11/16/2020
Today
9/27/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVUS
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Net Income
$-16,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.95 million
Optionable
Not Optionable
Beta
2.07

Key Executives

  • Mr. Jon S. Kuwahara CPA (Age 55)
    CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer
    Comp: $295.72k
  • Mr. Gregory J. Flesher (Age 50)
    Consultant
    Comp: $482.13k
  • Dr. David-Alexandre C. Gros M.D. (Age 48)
    CEO & Non Independent Director
  • Dr. Steven N. Perrin Ph.D. (Age 55)
    Pres, Chief Scientific Officer & Non Independent Director













NVUS Stock - Frequently Asked Questions

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics, Inc. (NASDAQ:NVUS) issued its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($5.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.64) by $3.87.
Read the conference call transcript
.

When did Novus Therapeutics' stock split?

Novus Therapeutics's stock reverse split before market open on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM) and vTv Therapeutics (VTVT).

What is Novus Therapeutics' stock symbol?

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

What is Novus Therapeutics' stock price today?

One share of NVUS stock can currently be purchased for approximately $2.75.

How much money does Novus Therapeutics make?

Novus Therapeutics (NASDAQ:NVUS) has a market capitalization of $3.95 million. The biopharmaceutical company earns $-16,010,000.00 in net income (profit) each year or ($21.58) on an earnings per share basis.

How can I contact Novus Therapeutics?

Novus Therapeutics' mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The official website for the company is novustherapeutics.com. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at investors@novustherapeutics.com.

This page (NASDAQ:NVUS) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.